Stan Berenshteyn
Stock Analyst at Wells Fargo
(2.09)
# 2,665
Out of 4,757 analysts
62
Total ratings
50%
Success rate
-9.55%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Stan Berenshteyn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HQY HealthEquity | Maintains: Overweight | $110 → $125 | $103.68 | +20.56% | 9 | Feb 26, 2025 | |
| DOCS Doximity | Maintains: Equal-Weight | $43 → $55 | $69.51 | -20.87% | 10 | Feb 7, 2025 | |
| HCAT Health Catalyst | Maintains: Overweight | $13 → $10 | $4.55 | +119.78% | 5 | Jan 21, 2025 | |
| OMCL Omnicell | Maintains: Equal-Weight | $49 → $40 | $37.82 | +5.76% | 12 | Jan 13, 2025 | |
| AMWL American Well | Upgrades: Overweight | $15 | $8.75 | +71.43% | 3 | Jan 13, 2025 | |
| VEEV Veeva Systems | Maintains: Overweight | $275 → $285 | $219.94 | +29.58% | 5 | Dec 6, 2024 | |
| ACCD Accolade | Maintains: Equal-Weight | $7 → $6 | $6.97 | -13.92% | 10 | Oct 11, 2024 | |
| GDRX GoodRx Holdings | Upgrades: Overweight | $10 | $4.94 | +102.43% | 6 | Mar 25, 2024 | |
| TDOC Teladoc Health | Maintains: Equal-Weight | $28 → $23 | $9.03 | +154.71% | 2 | Mar 6, 2023 |
HealthEquity
Feb 26, 2025
Maintains: Overweight
Price Target: $110 → $125
Current: $103.68
Upside: +20.56%
Doximity
Feb 7, 2025
Maintains: Equal-Weight
Price Target: $43 → $55
Current: $69.51
Upside: -20.87%
Health Catalyst
Jan 21, 2025
Maintains: Overweight
Price Target: $13 → $10
Current: $4.55
Upside: +119.78%
Omnicell
Jan 13, 2025
Maintains: Equal-Weight
Price Target: $49 → $40
Current: $37.82
Upside: +5.76%
American Well
Jan 13, 2025
Upgrades: Overweight
Price Target: $15
Current: $8.75
Upside: +71.43%
Veeva Systems
Dec 6, 2024
Maintains: Overweight
Price Target: $275 → $285
Current: $219.94
Upside: +29.58%
Accolade
Oct 11, 2024
Maintains: Equal-Weight
Price Target: $7 → $6
Current: $6.97
Upside: -13.92%
GoodRx Holdings
Mar 25, 2024
Upgrades: Overweight
Price Target: $10
Current: $4.94
Upside: +102.43%
Teladoc Health
Mar 6, 2023
Maintains: Equal-Weight
Price Target: $28 → $23
Current: $9.03
Upside: +154.71%